Tactile Systems Technology (NASDAQ:TCMD) Now Covered by Analysts at Lake Street Capital

Lake Street Capital initiated coverage on shares of Tactile Systems Technology (NASDAQ:TCMD) in a report published on Friday morning, MarketBeat.com reports. The firm issued a buy rating and a $23.50 target price on the stock.

Several other equities research analysts have also issued reports on the stock. William Blair upgraded shares of Tactile Systems Technology to a “strong-buy” rating in a research note on Tuesday, August 5th. B. Riley reiterated a “neutral” rating and issued a $13.00 price target (up from $12.00) on shares of Tactile Systems Technology in a research note on Tuesday, August 5th. Finally, Wall Street Zen raised shares of Tactile Systems Technology from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $16.83.

Tactile Systems Technology Stock Up 8.8%

Shares of TCMD stock opened at $15.20 on Friday. The company has a current ratio of 3.79, a quick ratio of 3.36 and a debt-to-equity ratio of 0.11. Tactile Systems Technology has a 1 year low of $8.61 and a 1 year high of $21.10. The firm’s fifty day moving average price is $12.92 and its two-hundred day moving average price is $11.90. The firm has a market capitalization of $338.84 million, a P/E ratio of 24.52 and a beta of 1.04.

Tactile Systems Technology (NASDAQ:TCMD) last issued its quarterly earnings results on Monday, August 4th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.05. Tactile Systems Technology had a net margin of 5.06% and a return on equity of 7.72%. The firm had revenue of $78.91 million for the quarter, compared to analyst estimates of $73.93 million. Tactile Systems Technology has set its FY 2025 guidance at EPS. On average, equities analysts predict that Tactile Systems Technology will post 0.7 EPS for the current fiscal year.

Insider Activity at Tactile Systems Technology

In related news, CEO Sheri Louise Dodd sold 7,762 shares of Tactile Systems Technology stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $12.36, for a total transaction of $95,938.32. Following the completion of the sale, the chief executive officer owned 173,479 shares of the company’s stock, valued at approximately $2,144,200.44. The trade was a 4.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 2.50% of the company’s stock.

Institutional Trading of Tactile Systems Technology

Hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC boosted its holdings in shares of Tactile Systems Technology by 64,350.0% during the 1st quarter. GAMMA Investing LLC now owns 2,578 shares of the company’s stock worth $34,000 after buying an additional 2,574 shares during the period. EP Wealth Advisors LLC bought a new stake in shares of Tactile Systems Technology during the 1st quarter worth about $138,000. Algert Global LLC bought a new stake in shares of Tactile Systems Technology during the 1st quarter worth about $160,000. Oxford Asset Management LLP bought a new stake in shares of Tactile Systems Technology during the 2nd quarter worth about $124,000. Finally, Pinnacle Wealth Management Advisory Group LLC bought a new stake in shares of Tactile Systems Technology during the 2nd quarter worth about $134,000. Institutional investors own 83.43% of the company’s stock.

Tactile Systems Technology Company Profile

Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.